LOGIN

International Epidemiology Databases to Evaluate AIDS

Home >> Publications >> Virologic Response in Children Treated with Abacavir Compared with Stavudine-Based Antiretroviral Treatment - A South African Multi-Cohort Analysis.

Publication

Author(s):

Technau KG, Schomaker M, Kuhn L, Moultrie H, Coovadia A, Eley B, Rabie H, Wood R, Cox V, Vizcaya LS, Muchiri E, Davies MA; for the IeDEA Southern Africa Paediatric Collaboration.

Pub Title:

Virologic Response in Children Treated with Abacavir Compared with Stavudine-Based Antiretroviral Treatment - A South African Multi-Cohort Analysis.

Pub Date:

Jun 30 2014

Pub Region(s):

Southern Africa

Journal:

Title: 
Pediatr Infect Dis J
Link: 
http://journals.lww.com/pidj/pages/articleviewer.aspx?year=9000&issue=00000&article=98122&type=abstract

PubMed: 24378944
Pub PDF:

Abstract
BACKGROUND:
Initiation criteria and pediatric antiretroviral treatment (ART) regimens have changed over the past few years in South Africa. We reported worse early virological outcomes associated with the use abacavir (ABC)-based regimens at one large site: here we expand this analysis to multiple sites in the IeDEA-Southern Africa collaboration.

METHODS: Data for 9543 ART-naïve children <16 years at treatment initiation started on either stavudine/lamivudine (d4T/3TC) or ABC/3TC with efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) treated at six clinics in Johannesburg and Cape Town, South Africa, were analysed with Chi-square tests and logistic regression to evaluate viral suppression at six and twelve months.

RESULTS: Prevalence of viral suppression at six months in 2174 children started on a d4T-based LPV/r regimen was greater (70%) than among 438 children started on an ABC-based LPV/r regimen (54%, p<0.0001). Among 3189 children started on a d4T-based EFV regimen a higher proportion (86%) achieved suppression at six months compared to 391 children started on ABC-containing EFV regimens (78%, p<0.0001). Relative benefit of d4T vs. ABC on six month suppression remained in multivariate analysis after adjustment for pre-treatment characteristics, cohort and year of program (LPV/r - OR 0.57 [CI: 0.46-0.72]; EFV - OR 0.46 [CI: 0.32-0.65]).

CONCLUSION: This expanded analysis is consistent with our previous report of worse virological outcomes after ABC was introduced as part of first-line ART in South Africa. Whether due to the drug itself or coincident with other changes over time, continued monitoring and analyses must clarify causes and prevent suboptimal long term outcomes.

 

The following websites provide guidelines and policies when citing from PubMed®: http://www.ncbi.nlm.nih.gov/books/NBK7243/
http://www.nlm.nih.gov/bsd/policy/cit_format.html

Citation:

Technau KG, Schomaker M, Kuhn L, Moultrie H, Coovadia A, Eley B, Rabie H, Wood R, Cox V, Vizcaya LS, Muchiri E, Davies MA; for the IeDEA Southern Africa Paediatric Collaboration. Virologic Response in Children Treated with Abacavir Compared with Stavudine-Based Antiretroviral Treatment - A South African Multi-Cohort Analysis. Pediatr Infect Dis J. 2013 Dec 30. [Epub ahead of print] PubMed PMID: 24378944.